Human Papillomavirus Prevalence, Viral Load and Cervical Intraepithelial Neoplasia in HIV-Infected Women

José E. Levi, Maria C.S. Fink, Cynthia L.M. Canto, Nadily Carretiero, Regina Matsubara, Iara Linhares, Gérson B. das Dores, Adauto Castelo, Aluísio Segurado, David E. Uip and José Eluf Neto

HIV-infected women from São Paulo city were enrolled in a cross-sectional study on Human Papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN) prevalence and their association with laboratory markers of AIDS, namely HIV viral load and CD4+ cell counts. A cervical specimen was collected and submitted to Hybrid Capture, a test for HPV viral load determination. HPV-DNA was detected in 173 of 265 women (64.5%). Twenty (7.5%) women were infected by one or more low-risk viruses, 89 (33%) by one or more high-risk viruses, and 64 (24%) harbored at least one HPV type from each risk group. Abnormal smears were observed in 19% of the patients, though there were no invasive carcinomas. Severely immunosuppressed patients (CD4/µL <100) were at the greatest risk of having a cytological abnormality and a high high-risk HPV viral load.

Key Words: Human Papillomavirus, cervical intraepithelial neoplasia, HIV-infected women, viral load, AIDS.

Human Papillomavirus (HPV) is the causative agent of cervical cancer and its precursor disease, known as squamous intraepithelial lesion (SIL). Several studies have reported that these HPV-induced lesions are more common [1] and have a worse outcome in Human Immunodeficiency Virus (HIV) infected women [2]. Therefore, investigating how this virus interacts with HIV disease in co-infected patients is of great importance, even more so in the context of the increasing incidence of AIDS among women in Brazil. The aim of this study was to determine the prevalence of HPV and SIL, and to compare markers of HIV disease, specifically CD4 counts and HIV viral load in a group of HIV-infected women from São Paulo city.

Materials and Methods

Patients: Between November 1997 and September 1999, 265 HIV infected women making a routine gynecological visit at the outpatient clinic of the Instituto de Infectologia Emílio Ribas or the Casa da AIDS were invited to participate in the study. Patients were included in the study if they had confirmed HIV infection, were being treated as outpatients and were willing give written, informed consent. This study was approved by the Ethics Committees of both institutions.

Biological samples: During the visit, blood was collected for a CD4 count and HIV viral load determination. In addition, a cervical smear was obtained for cytological analysis and cervicovaginal cells collected with a brush (Digene Cervical Sampler, Digene do Brasil, São Paulo-SP) that was immediately placed on Sample Transport Medium (STM, Digene...
do Brasil, São Paulo-SP) and brought the same day to
the virology laboratory of the Instituto de Medicina
Tropical.

Cytological analysis: Cervical smears were stained
by the Papanicolau method and classified into: Normal, Inflammatory, grade 1 to 3 Cervical Intra-
epithelial Neoplasia (CIN) and Invasive Carcinoma.

HIV: Plasma was separated within 6 hours after the
blood was drawn, and then frozen at –20°C. Viral
load was determined with an RT-PCR based kit,
Amplicor HIV-1 Monitor (version 1.0, Roche
Diagnóstica, São Paulo – SP, Brazil). The detection
threshold was 400 copies/mL.

HPV: HPV detection and quantitation was assessed
by the Hybrid Capture II (HC II) method, a non-
isotopic signal amplification technique based on the
hybridization of biotinylated RNA probes to the DNA
of HPV in the samples. The RNA-DNA hybrids were
immobilized in microplate wells by an antibody
adsorbed to the well surface. A cocktail of probes for
low-risk HPV types (group A, including HPV types 6,
11, 42, 43, and 44) and high-risk types (group B,
including HPV 16, 18, 31, 33, 35, 39, 45, 51, 53, 56,
58, 59, and 68) allowed for the discrimination of the
HPV group present in the sample, though the
characterization of individual types was not attempted.
Viral load was estimated by comparison with the signal
generated by 1 pg/mL of HPV. Samples giving a signal
greater than 1 were considered “positive” for the
respective HPV group.

The samples were denatured upon arrival at the lab
and an aliquot was removed for DNA precipitation for
other molecular analyses. Denatured samples were then
transported frozen to Digene do Brasil, where HC II
analysis was completed.

Results

Two hundred and sixty-five HIV-infected women
were investigated. They were predominantly young
(range = 18-67 years; mean age = 32.4 ± 7.7 years;
median = 32 years), with CD4 counts ranging from 8
to 978 cells/µL (mean = 296.84 ± 174.72 cells/µL;
median = 285 cells/µL) and HIV viral loads ranging
from undetectable (< 400 copies/mL) to above the
superior limit of the detection method (> 750,000
copies/mL) (mean 62,235 ± 145,884 copies/mL;
median = 5,764 copies/mL). For the purpose of
statistical analysis, samples in which HIV RNA was
undetectable were arbitrarily ascribed as 100 copies/
ml and those > 750,000 copies/mL were assigned
1,000,000 copies/mL. Among the 265 women, HPV
dNA was present in 173 (64.5%). Twenty (7.5%)
women were infected by one or more low-risk viruses,
89 (33%) women by one or more high-risk viruses,
and 64 (24%) women harbored at least one HPV type
from each risk group. Ten cytological smears were not
analyzed due to the absence of cervical cells (2),
hemorrhage (2), broken slide (2) and lost slide (4). Of
the remaining 255, 48 presented alterations compatible
with CIN (19%). There was no case of invasive
carcinoma. The majority (80%, N=210) of the patients
were under some kind of anti-retroviral treatment
regime (Table 1).

Age: Age was not significantly different among women
with positive versus negative HC II results. The
prevalence of HPV infection and CIN in the various
age groups is depicted in Figure 1. Younger women
(18-25 years) tended to have a higher prevalence of
CIN and of low and high-risk HPV types; CD4 counts
and HIV RNA levels did not differ among the age
groups (data not shown).

CD4: A CD4 count lower than 100 cells/µL was highly
predictive of concurrent infection with one or more high-
risk HPVs. Seventy-eight percent of the patients within
this lower range of CD4 counts were positive for high-
risk HPVs by HC II test, whereas about 94% of probe-
B-negative individuals had CD4 counts higher than 100
cells/µL (Table 2). Extremely immunosuppressed
women (< 100 cells/µL) had a greater chance of bearing
a dysplastic smear in comparison to those with
Table 1. Demographic, clinical and laboratory data of the women enrolled in the study, according to their Hybrid Capture results

<table>
<thead>
<tr>
<th>Hybrid Capture (N= 265)</th>
<th>Age Years*</th>
<th>HIV Viral Load* Copies/mL</th>
<th>CD4/µL*</th>
<th>HPV Viral Load* (RLU/PCA or PCB)</th>
<th>CIN Cytology</th>
<th>On antiretroviral therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative (34%; N=92)</td>
<td>34 ± 7.2</td>
<td>38,425 ± 130,987</td>
<td>364.7 ± 183.8</td>
<td>5 (5%)</td>
<td>67 (73%)</td>
<td></td>
</tr>
<tr>
<td>Positive low risk (7.5%; N=20)</td>
<td>32 ± 7.7</td>
<td>65,206 ± 90,676</td>
<td>237.7 ± 114.4</td>
<td>203.28 ± 400.17</td>
<td>5 (2%)</td>
<td>13 (65%)</td>
</tr>
<tr>
<td>Positive high risk (33%; N= 89)</td>
<td>33 ± 8.3</td>
<td>53,735 ± 112,577</td>
<td>288 ± 161.9</td>
<td>348.29 ± 570.58</td>
<td>19 (22%)</td>
<td>74 (83%)</td>
</tr>
<tr>
<td>Positive low and high risk (24%; N=64)</td>
<td>29 ± 6.2</td>
<td>106,012 ± 204,466</td>
<td>229 ± 161.5</td>
<td>263.55 ± 495.71</td>
<td>19 (30%)</td>
<td>56 (87.5%)</td>
</tr>
</tbody>
</table>

* Numbers represent mean ± 1 standard deviation.

Table 2. HIV, HPV and cytology according to the CD4/µL count

<table>
<thead>
<tr>
<th>CD4/µL</th>
<th>Prevalence of CIN (1-3) on Pap Smear</th>
<th>HIV Viral Load (mean, copies/mL)</th>
<th>HPV Viral Load RLU/PCA (median)</th>
<th>HPV Viral Load RLU/PCB (median)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;100. N=32</td>
<td>37.50%</td>
<td>106,512</td>
<td>14.11</td>
<td>324.96</td>
</tr>
<tr>
<td>101-200. N=52</td>
<td>27.00%</td>
<td>100,748</td>
<td>462.25</td>
<td>178.06</td>
</tr>
<tr>
<td>201-300. N=58</td>
<td>8.70%</td>
<td>54,356</td>
<td>5.39</td>
<td>220.21</td>
</tr>
<tr>
<td>301-400. N=59</td>
<td>15.25%</td>
<td>37,008</td>
<td>8.07</td>
<td>204.32</td>
</tr>
<tr>
<td>&gt;400 N=62</td>
<td>13.00%</td>
<td>42,079</td>
<td>17.63</td>
<td>15.01</td>
</tr>
</tbody>
</table>

Table 3. HPV, CD4 and HIV viral load according to cytological results

<table>
<thead>
<tr>
<th>Cytology</th>
<th>Normal/Inflammatory N=207</th>
<th>CIN 1-3 N=48</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4/µL (mean + SD)</td>
<td>310.4 ± 173.5</td>
<td>233.2 ± 171.8</td>
</tr>
<tr>
<td>HIV Viral Load (mean + SD)</td>
<td>58,777 ± 150,829</td>
<td>87,667 ± 137,316</td>
</tr>
<tr>
<td>AGE (mean + SD)</td>
<td>33 ± 7.6</td>
<td>31 ± 7.8</td>
</tr>
<tr>
<td>POSITIVE A</td>
<td>7.25%</td>
<td>10.42%</td>
</tr>
<tr>
<td>POSITIVE B</td>
<td>31.40%</td>
<td>39.60%</td>
</tr>
<tr>
<td>POSITIVE A and B</td>
<td>20.30%</td>
<td>39.60%</td>
</tr>
<tr>
<td>HPV Viral Load RLU/PCB (Mean + SD)</td>
<td>428.6 ± 684.65</td>
<td>1,194.53 ± 888.18</td>
</tr>
</tbody>
</table>
**Figure 1.** Prevalence of HPV group A, B and both and CIN according to age group

![Bar chart showing HPV prevalence by age group](chart1.png)

**Figure 2.** Low-risk and high-risk HPV positivity and prevalence of CIN according to HIV-1 viral load

![Bar chart showing HPV positivity by viral load](chart2.png)
CD4 > 100 cells/µL (p = 0.004; OR = 3.11) and of being infected by a high-risk group HPV (p = 0.01; OR = 2.93).

**HIV Viral Load:** As expected, HIV viral load was less predictive than CD4 cell counts for both high-risk HPV detection and altered cytology. Individuals with a viral load higher than 30,000 copies/mL had a prevalence of high-risk HPVs similar to those harboring less than 30,000 copies/mL (Figure 2), but the occurrence of concomitant low and high-risk HPVs and of CIN was higher in patients with HIV viral loads above 30,000 copies/mL.

**Squamous Intraepithelial Lesions (SIL):** The overall prevalence of altered cytological smears was 19% (48 altered smears among 255 readable slides). These altered cytologies can be further divided into high-grade SILs (HSIL), corresponding to CIN2 (13 patients; 5%) and CIN3 (5 patients; 2%) and low-grade SILs (LSIL), corresponding to CIN 1 (30 patients; 12%). Five patients with prevalent SILs had a negative HC II test and five were positive for the low-risk probe only. The sensitivity of the high-risk probe for a concomitant CIN diagnosis was 80% (38/48). The specificity was 48% (99/207), due to the high prevalence of HPV in this population. The positive predictive value of the HCII test for an altered cytology was 26% (38/146) while the negative predictive value was very high at 91% (99/109). In summary, as illustrated in Table 3, patients with a CIN diagnosis based on cytology were more severely immunosuppressed and had higher HIV and HPV viral loads, in comparison with those with normal/inflammatory Pap smears. The low prevalence of each CIN grade precluded an individual analysis; instead we preferred to analyze them all together.

**Discussion**

Human Papillomaviruses were frequent in this population of HIV-infected women. In fact, the observed prevalence of 66% is comparable to the 63.2% found by Massad and cols.[3] who made a PCR analysis of cervicovaginal washes from 1,517 HIV-infected North-American women and to the 56% found in HIV-infected Senegalese commercial sex workers [4]. In another study done on 141 HIV-infected women from Santos – Brazil, HPV DNA was detected by PCR in 80.8% of the patients [5]. This high prevalence of HPV is not unexpected since the majority of these women were infected by sexual transmission, a common route for both HIV and HPV acquisition. Similarly to what is found in HIV-seronegative populations, the high-risk group HPV's were more prevalent than those of the low-risk group and women from 18-25 years of age had the highest rate of infection (Figure 1).

Cervical abnormalities, determined by cytological analysis, were found in 48 women (19%) but only 5 had high-grade lesions (2%, CIN3) and no invasive carcinomas were observed. A strong correlation was found between immunosuppression, as measured by CD4 counts, and prevalent SILs as 37.5% of the patients with CD4/µL < 100 had an important cytological alteration compared to 13% of the patients with CD4/µL > 400. Several authors have reported prevalences of 20-40% SIL in HIV seropositive women, varying accordingly to the population, immune status and antiretroviral therapy. Immunosuppression seems to have an influence both on HPV prevalence and viral load, as depicted in Table 2. Median HPV viral loads decreased with increasing CD4 counts; this was more evident in patients with over 400 cells/µL. This data suggests that HIV-mediated immunosuppression allows an increase in HPV replication that could enhance the detection rate, which would explain the higher HPV prevalence observed in these groups.

Five women with altered smears were negative in the HCII test, which could be explained by lesions caused by HPV types not detected by the HCII method or by an HPV viral load below the detection threshold. Alternatively, it could be due to misclassification of the Pap smear. Another five women with cytological evidence of CIN were reactive for the low risk probe only, a finding that is quite unusual in immunocompetent women, though it has been described in HIV-infected patients [6].

www.infecto.org.br/bjid.htm
In conclusion this study shows that the prevalence of HPV in HIV-infected women in São Paulo is very high, accompanied by an elevated rate of squamous intraepithelial lesions, which seem to be more common among severely immunosuppressed patients. Palefsky et al. [7] found evidence that the high rate of HPV in HIV-infected women is a result of reactivation of cumulative latent viruses rather than recent acquisition, and Sun et al. [8], who repeatedly tested HIV-infected women for HPV by PCR, observed a high rate of persistent HPV infection, a known risk factor for the development of SIL. Our results suggest that a close surveillance for cervical malignancies is warranted in HIV-infected women. The Hybrid Capture test could play an important role since it was found to be predictive of existing SILs in this and other studies [9]. Specifically, we think that this test would be useful in assuring the inexistence of HPV-induced lesions since it had a significant negative predictive value. The outcome of the SILs found in this population can only be assessed by a longitudinal study, in which the influence of the course of HIV disease must be controlled. At present it is not known if the introduction of HAART will have a favorable effect on SILs. Possibly, by allowing partial restoration of immune functions, patients will be able to clear HPV infection and SILs may regress, as observed by Heard et al. [10] after investigating HIV infected women on HAART for 5 months. On the other hand, due to the increase in patient survival, SIL lesions will have more time to progress and, if this is the case, we would expect an increase in the incidence of “in situ” and invasive carcinomas on HIV patients receiving HAART. A direct interaction between HPV and HIV is not supported by our data, since there was no clear correlation among the viral loads.

References